In short
Clinical trials are studying Incb000928 in people with fibrodysplasia ossificans progressiva, also called FOP. These studies aim to see whether it can help prevent new bone-forming lesions, and they also check safety and tolerability. The main trial listed is a Phase 2 study in adults or other eligible participants with FOP.
Key points
- Clinical trials are studying Incb000928 in people with fibrodysplasia ossificans progressiva, a rare condition also called FOP. The listed trial is a Phase 2 study with 60 participants and is designed to compare Incb000928 with placebo. Researchers are looking at whether it can prevent new heterotopic ossification, which means bone forming in the wrong place. The main measure is the number of new HO lesions seen on low-dose whole-body CT from the start of the study to Week 24. The trial is also designed to assess safety and tolerability.
Trial overview
The clinical trial listed for Incb000928 is PROGRESS, a Phase 2 study in people with Fibrodysplasia Ossificans Progressiva (FOP). It is an interventional study, which means participants receive a study treatment rather than only being observed.
The study is authorised and plans to enroll 60 participants. Its brief purpose is to determine whether Incb000928 can help prevent new heterotopic ossification (HO) lesions in people with FOP.
Study design and treatment groups
This trial is randomized, double-blind, and placebo-controlled. Randomized means participants are assigned by chance to a study group, double-blind means neither participants nor the study team know who gets which treatment, and placebo-controlled means one group receives a placebo for comparison.
The interventions listed are oral Incb000928 at 100 mg and placebo. The trial record provided does not give more detail about visit schedules or how long treatment lasts beyond the main outcome time point.
Who can participate
The target population is participants with Fibrodysplasia Ossificans Progressiva. The provided trial data do not list extra eligibility rules such as age limits, disease stage, or prior treatment history.
Because FOP is a rare condition, studies like this are usually small and focus on carefully selected participants who match the study criteria. In this record, the total planned enrollment is 60 people.
What researchers are measuring
The main primary outcome is the occurrence of new HO lesions measured by low-dose whole-body CT, excluding the head, from baseline to Week 24. Baseline means the starting point before treatment begins.
Low-dose whole-body CT is a scan that uses a lower amount of radiation to look for new bone lesions throughout the body. This outcome is important because it helps researchers see whether the study treatment may prevent new unwanted bone formation.
The trial summary also states that the study is evaluating efficacy, safety, and tolerability of Incb000928. Efficacy means how well the treatment works, safety means whether medical problems happen, and tolerability means how well participants can take the treatment during the study.
What the study may show
This trial is designed to learn whether Incb000928 can reduce or prevent new HO lesions in people with FOP. If the results are positive, they may support further research in this rare disease.
Because this is a Phase 2 study, the main focus is still early testing rather than final proof. The study is meant to give a clearer idea of whether the treatment has promise and whether it can be studied further in larger trials.